RNS Announcements

Grant of Options

20 February 2025

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that options ("Options") have been granted over a total of 9,050,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") to Steen Andersen, Chief Executive of ProBiotix, and certain other key employees of the Company. 

The options were granted on 19 February 2025 with an exercise price of 9.5p per share. The Options may be exercised within 10 years from the date of their grant, subject to satisfaction of commercially oriented performance criteria, which includes significant revenue targets. 

Option holders can only exercise Options once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

[email protected]

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited  
Aquis Corporate Adviser and Broker




Mark Anwyl

Duncan Vasey

Tel: 020 7220 9793

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals. 

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe. 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Steen Andersen

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

 

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor

a)

Name

ProBiotix Health plc

b)

LEI

98450048683CF0388C30

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 ordinary shares of 0.05p each

 ISIN: GB00BLNBFR86

b)

Nature of the transaction

Grant of Options

c)

Price(s) and volume(s)

5,000,000  ordinary shares @ 9.5p per share

d)

Aggregated information

- Aggregated volume

- Price

 

 

n/a

e)

Date of the transaction

19 February 2025

f)

Place of the transaction

n/a